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Background: Intracoronary administration of autologous bone marrow derived
mononuclear cells (BM-MNC) may improve remodeling of the left ventricle (LV)
after acute myocardial infarction (AMI) as shown by some, but not all clinical trials
published so far. Long-term durability of the treatment effect is less well
established.
Methods: In a multi-center study, we randomized 200 patients with large, success-
fully reperfused ST segment elevation myocardial infarction (STEMI) in a 1:1:1
pattern into an open-labeled control and two BM-MNC treatment groups. In the BM-
MNC groups cells were either administered “early”, i.e. 5-7 days, or “late”, i.e. 3-4
weeks after AMI. Cardiac magnetic resonance imaging (CMR) was performed at
baseline (bl) , after 4 and 12 months. The current analysis investigates the change from
bl to 12 months in global LV ejection fraction (LVEF), LV-volumes as well as scar
size and compares the two treatment groups with control. Furthermore the event rate
of a combined clinical endpoint consisting of death, recurrent AMI, recurrent coronary
revascularization or rehospitalization for heart failure is computed.
Results: The absolute change in LVEF from bl to 12 months was -1.879.84 % for
control (meanSD), -0.8810.50 % for the early treatment group and -0.7010.11 %
for the late treatment group. The difference between the groups is not signiﬁcant
(p ¼ 0.1571). Changes of NT-proBNP over time are more favorable for BM-MNC
groups compared to control. The combined endpoint occurred equally in all three
groups (9 vs. 9 vs. 8 events; ns). Overall, 1-year mortality was rather low (2.5%)
without signiﬁcant difference between groups.Table: Interaction between factor time and factor treatment
Time P for interaction
baseline 4 months 12 months
LVEDV – ml mean (SD)
control 153 (38) 180 (52) 170 (56) 0.1217
early 156 (41) 183 (55) 179 (61)
late 157 (37) 167 (45) 164 (47)
LVESV – ml mean (SD)
control 94 (33) 112 (46) 110 (53) 0.3200
early 100 (36) 117 (51) 118 (56)
late 100 (29) 107 (40) 107 (44)
nt-proBNP – pg/ml mean (SD)
control 1639 (1304) 686 (822) 643 (1075) 0.0458
early 2082 (2060) 639 (524) 421 (414)
late 2632 (5218) 749 (698) 429 (405)Conclusions: Among patients with STEMI and LV dysfunction following successful
reperfusion, intracoronary infusion of BM-MNC either at 5-7 days or 3-4 weeks after
AMI, did not improve LV-function at 12 months follow-up, compared to an open
labeled, randomized control group.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/CeTCT-150
First-in-man Experience with Transendocardial Injections of Bone
Marrow-Derived Mesenchymal Stem Cells in Idiopathic Dilated
Cardiomyopathy. The MYOCYTE trial
Ricardo Sanz-Ruiz1, Alberto Nuñez Garcia2, Jaime Elizaga3, Francisco Fdez-Aviles4
1Hospital General Universitario Gregorio Marañón, Madrid, Spain, 2HGUGregorio
Marañon, Madrid, Madrid, 3H Gregorio Marañon, Madrid, Spain, 4Hospital General
Universitario Gregorio Marañon, Madrid, Spain
Background: In patients (p) with ventricular dysfunction, stem cell therapy has been
studied mainly in the subset of ischemic heart disease. Here we present the rationale
and the ﬁrst results of the ﬁrst-in-man stem cell therapy trial in idiopathic dilated
cardiomyopathy (IDC).
Methods: The MYOCYTE trial (NCT 01957826) is a randomized, double blind and
placebo-controlled trial that will enroll 70 p with IDC, left ventricular ejection
fraction (LVEF) < 45%, II-III NYHA functional class and MVO2 12-21 ml/Kg/
min. In a ﬁrst pilot phase, 10 p will be all treated with bone marrow-derived
mesenchymal stem cells (MSC) through 15 transendocardial injections (NOGA XP)
in the anterior wall of the left ventricle. In a second phase, 60 p will be radomized
in a 3:1 ratio to receive MSC or placebo. MSC are obtained after BM harvesting
and 3-4 weeks of culture in GMP facilities (dose: 30-40 million MSC). Primary
endpoints include MACE, adverse events, NYHA functional class, Holter moni-
toring, laboratory parameters and incidence of complications with the use of NOGA
XP catheters. Secondary endopints include MVO2 and functional capacity, quality
of life questionnaires, perfusion defects by MRI/SPECT, LVEF, ventricular volumes
and wall motion score index by echo/MRI, and electromechanical mapping
parameters by NOGA XP. Follow-up is scheduled for two years and independent
core-labs are included.
Results: So far, six p have been included in the trial, mean age was 60.09.6 years
and 5 p were male (83%). 83% had hypertension, 50% had diabetes mellitus, 67%
dyslipidemia and 33% were smokers. Baseline LVEF was 32.88.0% by echocar-
diography and 38.27.7% by MRI. Baseline MVO2 was 17.34.7 mL/kg/min, and
all p were in II NYHA funcional class. No MACE, adverse and arrhythmic events or
procedure-related complications have been observed so far. We have observed 1
sudden death 8.5 months after treatment and 1 contrast-induced renal failure. Echo-
cardiographic follow-up at 3 months is available for 4 p, showing a LVEF of
44.25.8%.
Conclusions: To the best of our knowledge this is the ﬁrst randomized trial with
transendocardial injection of MSC in these scenario. MSC injections seem to be safe,
and could be potentially beneﬁcial.
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Background: The overall low retention-rate of applied single cell suspensions limits
the efﬁcacy of current stem cell therapy concepts. Taking advantage of three
dimensional (3D) cellular self-assembly prior to transplantation may be beneﬁcial. We
investigate the principal feasibility of intramyocardial transplantation of in-vitro
generated stem-cell based 3D-microtissues (3D-MTs) in a porcine myocardial
infarction model.
Methods: 3D-MTs were generated from iron-oxide (MPIO) labeled human mesen-
chymal stem cells (hMSCs) using a modiﬁed hanging-drop method. Adult pigs (30-
40kg) with chronic MI underwent intramyocardial transplantation of 16x103 3D-MTs
(1250cells/MT; accounting for 2x107 single hMSCs) into the MI border-zone using a
3D NOGA mapping-guided, transcatheter approach. Follow-up (FU) was performed
for up to 6 weeks and in-vivo cell-tracking was done using serial Magnetic Resonance
Imaging (MRI), followed by PCR and immunohistochemistry.
Results: Intramyocardial transplantation of hMSC based 3D-MTs was successful in
all animals. During FU, no arrhythmogenic or neurological events occurred. Serial
MRI displayed intramyocardial presence of the 3D-MTs by detection MPIOs during
FU. Intramyocardial retention of 3D-MTs was conﬁrmed by PCR-analysis and was
further veriﬁed on histology and immunohistochemistry. 3D-MTs were viable, inte-
grated and showed intact micro-architecture.
Conclusions: We demonstrate the feasibility and safety of intramyocardial
transplantation of in-vitro generated human stem-cell based 3D-MTs. Multimodal
cell-tracking strategies comprising imaging and in-vitro tools allow for in-vivo
monitoring and post-mortem analysis of 3D-MTs. 3D cellular self-assembly prior to
transplantation may represent a promising application-format for stem-cell based
therapies.ll Therapy and Angiogenesis B45
